Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2022 16:05 ET | Source: Viridian Therapeutics, Inc

Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

-- Phase 1/2 clinical trial for VRDN-001 currently recruiting Thyroid Eye Disease (TED) patients at sites in the U.S. and Canada; top line proof of concept data expected in the third quarter of 2022...
May 03, 2022 08:00 ET | Source: Viridian Therapeutics, Inc

Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022

WALTHAM, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved...